Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ +5.21%48 Cash Ratio is 2.81 as of Dec. 2025, which is 25% below its 10-year median of 3.73. GuruFocus rates ASX:EZZ with a GF Score™ of 48/100 and a GF Value™ of A$1.48 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,382 Biotechnology companies, EZZ Life Science Holdings ranks worse than 51.09% on this metric.
EZZ Life Science Holdings has a Cash Ratio of 2.81. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for EZZ Life Science Holdings's Cash Ratio or its related term are showing as below:
ASX:EZZ'
s Cash Ratio Range Over the Past 10 Years
Min: 2.23 Med: 3.73 Max: 5.25
Current: 2.81
During the past 6 years, EZZ Life Science Holdings's highest Cash Ratio was 5.25. The lowest was 2.23. And the median was 3.73.
ASX:EZZ's Cash Ratio is ranked worse than 51.09% of 1382
companies
in the Biotechnology industry
Industry Median: 2.93
vs ASX:EZZ: 2.81
EZZ Life Science Holdings (ASX:EZZ) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
EZZ Life Science Holdings Cash Ratio Related Terms
EZZ Life Science Holdings Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EZZ vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) has a Cash Ratio of 2.81 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on EZZ Life Science Holdings and its competitors. This is 25% below median its historical median of 3.73. Over the past decade, EZZ Life Science Holdings' Cash Ratio has ranged from 2.23 to 5.25. According to the industry distribution chart, EZZ Life Science Holdings ranks #706 out of 1382 companies in the Biotechnology industry, placing it in the top 51.1%.
Is EZZ Life Science Holdings' Cash Ratio too high?
EZZ Life Science Holdings' current Cash Ratio of 2.81 is 25% below median its 10-year median of 3.73. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 5.25. The Biotechnology industry median Cash Ratio is 2.93. EZZ Life Science Holdings' value of 2.81 is 4.1% below this industry median. Based on the distribution chart, EZZ Life Science Holdings ranks #706 out of 1382 companies in the Biotechnology industry, which is below the industry midpoint. Overall, EZZ Life Science Holdings has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #706 out of 1382 companies for Cash Ratio. This places EZZ Life Science Holdings in the lower half of its industry. The industry median Cash Ratio is 2.93. EZZ Life Science Holdings' value of 2.81 is 4.1% below this benchmark. Historically, EZZ Life Science Holdings' own Cash Ratio has ranged from 2.23 to 5.25 over the past decade. While the company's 10-year median is 3.73 vs. the industry median of 2.93, EZZ Life Science Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EZZ Life Science Holdings's current Cash Ratio of 2.81 is 4.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on EZZ Life Science Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EZZ Life Science Holdings's current Cash Ratio is 2.81, which is 25% below median its own 10-year median of 3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.48, compared to a current price of A$0.51 — trading 65.9% below its estimated fair value. The current Cash Ratio is 2.81, which is 25% below median its 10-year median of 3.73 and 4.1% below the Biotechnology industry median of 2.93. EZZ Life Science Holdings' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current Cash Ratio is 2.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.51 is trading 65.9% below its estimated GF Value™ of A$1.48.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
Cash Ratio: 2.81 (25% below median its 10-year median of 3.73)
GF Value™: A$1.48 vs. price of A$0.51 (65.9% below fair value)
Industry Position: 4.1% below the Biotechnology median (#706 of 1382)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
48GF Score
Get the complete analysis for ASX:EZZ
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
